As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck & Co has axed two hepatitis drugs in its pipeline ... a deep undercutting of Epclusa’s list price of $74,760 for a 12 week course - and analysts think this move could spark a price ...

An acquisition by Merck was “hard to resist” given the company’s long history and expertise in drug development, experience ...

AstraZeneca and Merck & Co have cemented ... are already on Lynparza’s list of approved indications. Use in ovarian and breast cancer has already put the drug firmly on course to top the $1 ...

Merck's most important product is Keytruda, a cancer drug that has won approval to treat ... Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

We recently compiled a list of the 9 Best Dow Stocks to Buy According to Analysts. In this article, we are going to take a ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...